We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Alexandra
Lynch
Alexandra.Lynch@mbht.nhs.uk
Hilary
Thatcher
hilary.thatcher@mbht.nhs.uk
Alison
Birtle
alison.birtle@lthtr.nhs.uk
Malignant neoplasms of male genital organs
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Prostate cancer is the most commonly diagnosed male cancer, with more than 52,000 new cases in the UK 2018/191. Prostate Specific Antigen (PSA) is a blood test used to help diagnose Prostate Cancer (PC). However, raised PSA is not specific for PC and may be due to a urine infection, ejaculation or exercise. If the PSA is high, an MRI scan of the prostate is carried out to check for an abnormal appearance. This is useful but can still miss important cancers especially in younger men (< 50 years) and where the cancer is located in certain areas of the prostate. MRI is followed by uncomfortable prostate biopsies, which carry a risk of severe infection and bleeding but may still miss significant cancers.
In this study, patients undergoing investigations for suspected PC are asked to provide a sample of blood, urine and saliva to explore new markers for PC. Raman spectroscopy (RS) is a powerful light-scattering technique that can analyse these samples, providing information on the proteins, fats and carbohydrates, as well as DNA and RNA in these samples. Changes occur in the levels of these with PC, and by identifying these differences, it should be possible to distinguish between cancer and non-cancer. We already know from other studies that this is possible to see on prostate samples with very good accuracy, but more work is needed to be able to use that information in the clinic to benefit patients quickly.
Patients will have their usual management with MRI, prostate biopsies, confirmation of cancer (or not) by a pathology doctor and with biopsy samples also analysed by RS. The results from blood, urine and saliva are compared between the men with and without PC. We hope this could lead to less invasive and more accurate diagnostic tests for PC.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Validation of investigation /therapeutic procedures;
You can take part if:
You may not be able to take part if:
1. Active malignancy within two years prior to study inclusion ( not including non melanomatous skin carcinoma, previous non muscle invasive bladder cancer or in situ carcinoma of any site) 2. Any other conditions that in the Clinial PI opinion would be a contraindication to trial inclusion 3. Unable or unwilling to undergo prostate biopsies for any reason 4. Unable to or unwilling or provide sample of blood, saliva or urine. 5. Men who are subject to safeguarding such as those with dementia, learning disability or those who lack capacity. For this pilot feasibility study, men who do not have a satisfactory grasp of English will not be approached- due to the patient information sheets being written in English alone for this proof of concept study. However the local population in Morecambe Bay is predominantly English speaking, mainly Caucasian and with very few diagnoses of prostate cancer in the local BAME population, and it is not felt that this feasibility trial will disadvantage other patients in this pilot stage. However should there be an previously unidentified unmet need, this would be discussed with the Study Oversight group PPI members.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
Alison
Birtle
alison.birtle@lthtr.nhs.uk
Alexandra
Lynch
Alexandra.Lynch@mbht.nhs.uk
Hilary
Thatcher
hilary.thatcher@mbht.nhs.uk
The study is sponsored by UNIVERSITY HOSPITALS OF MORECAMBE BAY NHS FOUNDATION TRUST and funded by NORTH WEST CANCER RESEARCH (INCORPORATING CLATTERBRIDGE CANCER RESEARCH CCR) .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 53835
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
